232 top medical experts on Cystadenocarcinoma across 27 countries and 14 U.S. states, including 89 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants.

  1. Cystadenocarcinoma: A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)
  2. Clinical guidelines are the recommended starting point to understand initial steps and current protocols in any disease or procedure:
  3. Broader Categories (#Experts): and Serous Mucinous Cystic Neoplasms (1,447), Adenocarcinoma (5,212) and Narrower Categories: Mucinous Cystadenocarcinoma (943), Papillary Cystadenocarcinoma (614), Serous Cystadenocarcinoma (3,152).
  4. Clinical Trials ClinicalTrials.gov : at least 97 including 18 Active, 40 Completed, 12 Recruiting


  

        

                    


    Computing Expert Listing ...

);